Jim Cramer's Lightning Round: Palantir, Viking Therapeutics, Gartner, and More

Palantir Stock Analysis

• 💡 Jim Cramer remains bullish on Palantir, reiterating his belief that the stock will reach $200.
• 🎯 Despite some business wins for competitors, Cramer likes the company and would consider adding its CEO to his fantasy sports team.

Speculative Stock Picks

• 🚀 For Rich Tech Robotics, Cramer advises buying the stock but categorizes it as a speculative investment.
• ⚠️ He emphasizes that investors should accept the possibility of losing their entire investment in such speculative plays.

Weight Loss Drugs and Therapeutics

• 💊 Regarding Viking Therapeutics, Cramer suggests focusing on established leaders like Eli Lilly rather than settling for less prominent options.

Underpriced Stocks and Market Uncertainty

• 🔍 Cramer notes that Conmed (CMD) appears too cheap, indicating he needs to investigate further to understand why.
• 📊 For Gartner, Cramer expresses a 'wait and see' approach due to a disappointing last quarter, worried about potential underlying issues beyond a single bad report.

Profit Taking and Portfolio Management

• 💰 On Madison Square Garden Sports, Cramer suggests taking half of the profits given that it's not a top favorite and doesn't exhibit strong growth, while acknowledging the nice gains already made.